BIOMUNEX PHARMACEUTICALS

Biomunex presents new preclinical data on MAIT cell redirection approach at AACR 2024 meeting 🔬 ➡ Wednesday, April 10th, 2024, from 9.00 a.m. to 12:30 p.m ➡ San Diego Conference Centre, San Diego, California, USA #Biomunex #MAITengagers #AACR2024

Great to be here at the AACR in San Diego. 22,000 people focused on one thing...tackling cancer. Biomunex are contributing to this with an innovative approach to T-cell redirection: MAIT engagers. I will be presenting this at the Poster session on Wednesday morning.

Join Simon Plyte, CSO of Biomunex, at American Association for Cancer Research (AACR) 2024, at San Diego Convention Center, San Diego, CA, USA, and attend his poster presentation on MAIT engagers 🔬 ➡️ Poster No. 6708. ➡️ Poster session: Wednesday 10th April at 9.00 – 12.00 a.m. #Biomunex #AACR #AACR2024 #MAITengagers

Immunothérapie : une approche prometteuse basée sur une découverte de l’Institut Curie va être développée par Biomunex Partenaires depuis 2019, l’Institut Curie et BIOMUNEX PHARMACEUTICALS annoncent une nouvelle étape dans leur collaboration de recherche stratégique. Biomunex signe un accord de licence exclusif avec l’Institut Curie pour le développement clinique d’une nouvelle catégorie d’anticorps, capables de cibler, d’engager et de rediriger spécifiquement les cellules MAIT pour détruire les cellules cancéreuses. 👉 Un pas de plus vers de nouvelles immunothérapies de pointe, plus sûres et plus efficaces, au bénéfice des patients. Pour en savoir plus :

I'm delighted to attend BIO-Europe Spring, from March 18 to 20, 2024, in Barcelona, to meet colleagues and friends in the biopharma community. #Biomunex #BIOEurope #BIO2024

💭 “We are pleased to announce the signature of an exclusive license and exploitation agreement with Institut Curie, France's first and leading cancer research center, and a major historical partner of Biomunex, for the development of a new class of antibodies, the MAIT engagers. These MAIT engagers will be able to specifically target and engage MAIT cells to kill cancer cells”, said Dr. Pierre-Emmanuel Gerard, Founder and CEO of Biomunex. ➡ Biomunex, which was a 50% co-owner and the co-inventor of this unique innovative approach, now holds its full worldwide rights. Read the press release 🗞 https://lnkd.in/eiqDEpzB #Biomunex #MAITengagers #Immunotherapy

🎗️ Yesterday Sunday, 4th, it was World Cancer Day, we are proud to share our ongoing commitment to research against this devastating disease. At Biomunex Pharmaceuticals, we work tirelessly to advance pharmaceutical innovation and offer hope to patients affected by cancer. 🔬 The development of our BiXAb technology and innovative antibodies is progressing, particularly with our unique MAIT engagers, opening up new perspectives for safer and more effective treatments. #WorldCancerDay #MedicalInnovation #ClinicalTrials #FightCancer #Biomunex

Biomunex Pharmaceuticals announces the start of a Phase 1 clinical study for its first-in-class bispecific antibody for the treatment of cancer 🔔 This first-in-man trial conducted by Onward Therapeutics, under the license and co-development agreement, is a Phase 1 clinical trial for the evaluation of a bispecific antibody generated from Biomunex' proprietary BiXAb® platform. The enrollment of the first patient in the Phase 1 clinical trial for this BiXAb® candidate, demonstrates the potential of the BiXAb platform to generate clinical candidates. It also triggered the first clinical milestone to Biomunex by its partner. 🗞 For more information, read the press release: https://lnkd.in/eH47-xeJ #Biomunex #Immunotherapy #Oncolology #Biotech #BiXAb

Among the 7 new Challenges highlighted by President Macron during his trip to Toulouse, Biomunex is well placed in the “Bioproduction and life technologies” Challenge together with few other healthcare companies. According to France 2030, 8 biomedicines are now produced in France. The aim by 2030 is to secure our supply of biomaterials and bioenergy, while respecting our biodiversity. The selected project leaders are : Global Bioenergies, Blackleak, Calyxia, Néolithe, Aenitis Technologies, Affilogic, BioMérieux, Biomunex Pharmaceuticals, CellQuest, Kimialys, PathoQuest, Seripharm, Astraveus, Cell-Easy, Ceva, Encefa, MaaT Pharma, Human Cell Design. ✍ More information in the Le Figaro article: https://lnkd.in/d8eRJjfa #Biomunex #Immunotherapy #France2030

Understand our technology and outlooks in 3 questions🔬 Pierre-Emmanuel Gerard, founder and CEO, and Simon Plyte, CSO, are delighted to introduce you to Biomunex Pharmaceuticals and its BiXAb and BiXAb-MAIT engager technologies for generating bi- and multi-specific antibodies with high potential as game-changers for treating cancer. #Biomunex #Immunotherapy #MAITengager #BiXAb